Omeprazole Stada

Omeprazole, the active ingredient in Omeprazole Stada, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Omeprazole Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Omeprazole Stada belongs to the proton pump inhibitor class and is indicated for acid‑related gastrointestinal disorders. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with the condition.

Adverse reactions to Omeprazole Stada vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: typically self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: excess gas. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: renal inflammation. - Hypomagnesemia: low serum magnesium levels. - Stevens‑Johnson syndrome: severe skin reaction. - Hepatic injury: elevated liver enzymes or hepatitis. - Anaphylaxis: rare systemic allergic response.

When using Omeprazole Stada, consider the following safety measures: - Assess renal function: adjust use in patients with severe impairment. - Evaluate hepatic status: use cautiously in liver disease. - Review long‑term therapy: monitor for vitamin B12 deficiency and bone density loss. - Pregnancy and lactation: prescribe only if clearly needed. - Drug‑interaction review: check concomitant medications for potential clashes. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole Stada may affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased antiviral exposure, compromising HIV therapy. - Methotrexate (high dose): increased toxicity risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR, requiring closer monitoring. - Digoxin: possible increase in serum levels. - Phenytoin: reduced phenytoin concentrations, may need dose adjustment.